{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:21:39Z","timestamp":1761128499888,"version":"3.32.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1097\/01.bor.0000231901.19795.8a","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T18:12:58Z","timestamp":1149703978000},"page":"347-353","source":"Crossref","is-referenced-by-count":26,"title":["Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis"],"prefix":"10.1097","volume":"18","author":[{"given":"Arthur","family":"Kavanaugh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuhre","family":"Tutuncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Catalan-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.bor.0000167753.01168.bd","article-title":"Classification of the spondyloarthropathies","volume":"17","author":"Healy","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"key":"R3-5-20210128","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2002.004861","article-title":"Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age","volume":"62","author":"Chorus","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/ard.2005.036491","article-title":"Double blind, randomized, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis","volume":"64","author":"van Dendern","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.bor.0000159926.42761.dd","article-title":"Treatment update on spondyloarthropathy","volume":"17","author":"Anandarajah","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.semarthrit.2004.08.005","article-title":"Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis","volume":"34","author":"Davis","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor (infliximab) versus placebo in active spondyloarthropathy","volume":"46","author":"van den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","article-title":"Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/ard.2004.025130","article-title":"Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis","volume":"64","author":"Braun","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/keh584","article-title":"Persistent clinical response to the anti-TNF-\u03b1 antibody infliximab in patients with ankylosing spondylitis over 3 years","volume":"44","author":"Braun","year":"2005","journal-title":"Rheumatology"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor \u03b1","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R16-5-20210128","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","article-title":"Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis","volume":"44","author":"Brandt","year":"2005","journal-title":"Rheumatology"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"Davis","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.21330","article-title":"Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy","volume":"53","author":"Davis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"R21-5-20210128","first-page":"S208","article-title":"Major clinical response and partial remission in ankylosing spondylitis subjects treated with adalimumab: the ATLAS trial","volume":"52","author":"Davis","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"R22-5-20210128","first-page":"S211","article-title":"Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis: the ATLAS trial","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R23-5-20210128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/berh.2002.0250","article-title":"Imaging and scoring in ankylosing spondylitis","volume":"16","author":"Braun","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/rheumatology\/kei046","article-title":"Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumor necrosis factor agent infliximab","volume":"44","author":"Sieper","year":"2005","journal-title":"Rheumatology"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R26-5-20210128","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor \u03b1 receptor fusion protein etanercept","volume":"52","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R27-5-20210128","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/ard.2004.032441","article-title":"Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept","volume":"64","author":"Rudwaleit","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.21588","article-title":"Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data","volume":"53","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum (Arthritis Care Res)"},{"key":"R29-5-20210128","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R30-5-20210128","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"for the ASAS working group. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R33-5-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/ard.2003.018549","article-title":"Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy","volume":"64","author":"Kruithof","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R34-5-20210128","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1002\/art.21426","article-title":"Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies","volume":"52","author":"Kruithof","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R35-5-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/ard.62.6.561","article-title":"Up regulation of the production of tumor necrosis factor \u03b1 and interferon \u03b3 by T cells in ankylosing spondylitis during treatment with etanercept","volume":"62","author":"Zou","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R36-5-20210128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/art.10847","article-title":"Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab","volume":"48","author":"Zou","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R37-5-20210128","first-page":"1881","article-title":"The evolving use of TNF inhibitors in rheumatoid arthritis","volume":"31","author":"Kavanaugh","year":"2004","journal-title":"J Rheumatol"},{"issue":"Suppl IV","key":"R38-5-20210128","doi-asserted-by":"crossref","first-page":"iv65","DOI":"10.1136\/ard.2005.042440","article-title":"Health economics: implications for novel antirheumatic therapies","volume":"64","author":"Kavanaugh","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R40-5-20210128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-996-0039-x","article-title":"Outcome measures in psoriatic arthritis","volume":"7","author":"Kavanaugh","year":"2005","journal-title":"Curr Rheumatol Rep"},{"key":"R41-5-20210128","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"R42-5-20210128","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R43-5-20210128","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R44-5-20210128","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"R46-5-20210128","first-page":"S281","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week result from IMPACT 2","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R48-5-20210128","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: result of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"R49-5-20210128","first-page":"S211","article-title":"Psoriatic arthritis patients have different rates of adverse events than rheumatoid arthritis patients when treated with TNF inhihitors: analysis from CORRONA Database","volume":"52","author":"Cassell","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.bor.0000231901.19795.8a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T07:42:02Z","timestamp":1736408522000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200607000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.bor.0000231901.19795.8a","relation":{},"ISSN":["1040-8711"],"issn-type":[{"type":"print","value":"1040-8711"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}